Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors

The Pharmacogenomics Journal volume 17, pages 237–241 (2017)Cite this article

Subjects

Abstract

Psoriasis is a multifactorial skin disease affecting ~2% of world’s population, causing a dramatic decrease in patients’ quality of life and a significant increase in health-care expenses. Biological agents such as the anti-TNFα ones had an enormous impact in patients’ therapy; however, a significant proportion of them do not respond well, an outcome attributed mainly to genetic factors. Recently, in a large European cohort of rheumatoid arthritis patients we have shown association with variation in the receptors that correspond to the Fc portion of the biological agents. As both diseases share common immunological fingerprints, we examined the hypothesis that they share common pharmacogenetic markers. Analysis of FCGR2A-H131R and FCGR3A-V158F polymorphisms in 100 psoriasis patients showed association only with respect to FCGR3A-V158F and response to etanercept (P=0.018). Interestingly, no association was found between FCGR2A-H131R and response to anti-TNFα therapy (P=0.882). This study suggests a role for FCGR3A-V158F polymorphism unique for psoriasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Lowes MA, Bowcock AM, Krueger JG . Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866–873.

    Article  CAS  PubMed  Google Scholar 

  2. Lobo ED, Hansen RJ, Balthasar JP . Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645–2668.

    Article  CAS  PubMed  Google Scholar 

  3. Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J . Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol 2015; 24: 79.

    Google Scholar 

  4. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 2014; 15: 707–716.

    Article  CAS  PubMed  Google Scholar 

  5. Highton J, Carlisle B, Palmer DG . Changes in the phenotype of monocytes/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 1995; 102: 541–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shinohara S, Hirohata S, Inoue T, Ito K . Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis. J Rheumatol 1992; 19: 211–215.

    CAS  PubMed  Google Scholar 

  7. Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Kruger-Krasagaki S et al. Pharmacogenetic analysis of TNF, TNFRSF1A and TNFRSF1B polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 2012; 16: 29–34.

    Article  CAS  PubMed  Google Scholar 

  8. Prieto-Pérez R, Cabaleiro T, Daudén E, Ochoa D, Román M, Abad-Santos F . Pharmacogenetics of topical and systemic treatment of psoriasis. Pharmacogenomics 2013; 14: 1623–1634.

    Article  PubMed  Google Scholar 

  9. Nimmerjahn F, Ravetch JV . Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19–28.

    Article  CAS  Google Scholar 

  10. Nimmerjahn F, Ravetch JV . Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34–47.

    Article  CAS  PubMed  Google Scholar 

  11. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D . Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52: 2693–2696.

    Article  CAS  PubMed  Google Scholar 

  12. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 448–452.

    Article  CAS  PubMed  Google Scholar 

  13. Rooryck C, Barnetche T, Richez C, Laleye A, Arveiler B, Schaeverbeke T . Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008; 26: 340–342.

    CAS  PubMed  Google Scholar 

  14. Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C et al. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Clin Exp Rheumatol 2013; 31: 189–194.

    PubMed  Google Scholar 

  15. Montes A, Perez-Pampin E, Narváez J, Cañete JD, Navarro-Sarabia F . Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 2014; 24: 238–245.

    CAS  PubMed  Google Scholar 

  16. Montes A, Perez-Pampin E, Joven B, Carreira P, Fernández-Nebro A, Del Carmen Ordóñez M et al. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics 2015; 16: 333–345.

    Article  CAS  PubMed  Google Scholar 

  17. Bowcock AM, Krueger JG . Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699–711.

    Article  CAS  PubMed  Google Scholar 

  18. Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014; 70: 146–167.

    Article  PubMed  Google Scholar 

  19. Su K, Wu J, Edberg JC, McKenzie SE, Kimberly RP . Genomic organization of classical human low-affinity Fcgamma receptor genes. Genes Immun 2002; S1: S51–S56.

    Article  Google Scholar 

  20. Faul F, Erdfelder E, Buchner A, Lang AG . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149–1160.

    Article  PubMed  Google Scholar 

  21. Semble AL, Davis SA, Feldman SR . Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol 2014; 15: 37–43.

    Article  PubMed  Google Scholar 

  22. Cheng J, Feldman SR . The cost of biologics for psoriasis is increasing. Drugs Context 2014; 3: 212–266.

    Article  Google Scholar 

  23. Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F . Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013; 13: 297–305.

    Article  PubMed  Google Scholar 

  24. Li X, Ptacek TS, Brown EE, Edberg JC . Fcgamma receptors: structure, function and role as genetic risk factors in SLE. Genes Immun 2009; 10: 380–389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1547–1552.

    Article  PubMed  Google Scholar 

  26. Nishio S, Yamamoto T, Kaneko K, Tanaka-Matsumoto N, Muraoka S et al. Pharmacokinetic study and Fcgamma receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab. Mod Rheumatol 2009; 19: 329–333.

    Article  CAS  PubMed  Google Scholar 

  27. Julià M, Guilabert A, Lozano F, Suarez-Casasús B, Moreno N, Carrascosa JM et al. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol 2013; 149: 1033–1039.

    Article  PubMed  Google Scholar 

  28. van der Pol W, van de Winkel JG . IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998; 48: 222–232.

    Article  CAS  PubMed  Google Scholar 

  29. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059–1070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jani M, Barton A, Ho P . Pharmacogenetics of treatment response in psoriatic arthritis. Curr Rheumatol Rep 2015; 17: 518–527.

    Article  Google Scholar 

  31. Cacabelos R . Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res 2014; 75: 348–365.

    Article  CAS  PubMed  Google Scholar 

  32. Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P et al. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenomics J 2015; e-pub ahead of print.

Download references

Acknowledgements

We are very grateful to all the participants of the study. This work was supported by the postgraduate program ‘Molecular Biology and Genetics Applications - Diagnostic Markers’ of the Department of Biochemistry and Biotechnology, University of Thessaly, Greece.

Author information

Authors and Affiliations

  1. Department of Biochemistry and Biotechnology, Laboratory of Genetics, Comparative and Evolutionary Biology, University of Thessaly, Larissa,, Greece

    E Mendrinou, D Papadopoulou, L Aggelou, C Sarri, Z Mamuris, T Sarafidou & Y Vasilopoulos

  2. 2nd Dermatology Department, Medical School, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece

    A Patsatsi, A Kyriakou & D Sotiriadis

  3. Department of Dermatology, University General Hospital Larissa, University of Thessaly, Larissa,, Greece

    E Zafiriou & A Roussaki-Schulze

Authors
  1. E Mendrinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Patsatsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Zafiriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Papadopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Aggelou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Sarri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z Mamuris
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Kyriakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Sotiriadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Roussaki-Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Sarafidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Vasilopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Vasilopoulos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mendrinou, E., Patsatsi, A., Zafiriou, E. et al. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors. Pharmacogenomics J 17, 237–241 (2017). https://doi.org/10.1038/tpj.2016.16

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2016.16

Search

Advanced search

Quick links